tulisokibart vs XmAb942
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
tulisokibart
Developed by Merck & Co.
NCT06052059 · Phase 3 · active, not recruiting
First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2037 · NCT06651281 (registry estimate)
Reported efficacy
Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)
Result source: NCT06052059
XmAb942
Developed by Xencor
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT06619990 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | tulisokibart | XmAb942 |
|---|---|---|
| Clinical remission (induction) | 26.5% vs 1.5%+25 vs placeboNCT049967971 other result
| —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT06052059 | —Not reported |
| Clinical response (induction) | 66.2% vs 22.4%+43.8 vs placeboNCT049967971 other result
| —Not reported |
| Endoscopic improvement (induction) | 36.8% vs 6%+30.8 vs placeboNCT049967971 other result
| —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT06052059 | —Not reported |
Clinical remission (induction)
- tulisokibart
- 26.5% vs 1.5%+25 vs placeboNCT04996797
1 other result
- 31.6% vs 10.8% NCT04996797
- XmAb942
- —Not reported
Clinical remission (maintenance)
- tulisokibart
- —Trial running · NCT06052059
- XmAb942
- —Not reported
Clinical response (induction)
- tulisokibart
- 66.2% vs 22.4%+43.8 vs placeboNCT04996797
1 other result
- 55.3% vs 32.4% NCT04996797
- XmAb942
- —Not reported
Endoscopic improvement (induction)
- tulisokibart
- 36.8% vs 6%+30.8 vs placeboNCT04996797
1 other result
- 36.8% vs 18.9% NCT04996797
- XmAb942
- —Not reported
Corticosteroid-free remission (maintenance)
- tulisokibart
- —Trial running · NCT06052059
- XmAb942
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
XmAb942: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. tulisokibart: 3 of 4 rows · XmAb942: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tulisokibart |
|---|---|
| Dropout rate | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more resultn/a: no completion milestoneCohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Discontinued due to AEs | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result0%Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Serious AEs | 1.1%All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result—Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Most frequent reported AEs | covid-19 5.6% (placebo 4.5%) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tulisokibart
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tulisokibart's landscape · XmAb942's landscape